Authors: Yi-Wen Tien, Sheng-Mou Hsiao, Chien-Nan Lee, and Ho-Hsiung Lin
Published in: International Urogynecology Journal. 2017;28(3):469-476
1. PUBLISHED IN HIGH IMPACT PEER-REVIEWED UROGYNECOLOGY JOURNAL
The International Urogynecology Journal is the official journal of the International Urogynecological Association (IUGA). It covers active topics on urogynecology and pelvic floor disorders and presents interdisciplinary coverage of all aspects of the field.
2. METHODOLOGY
Thirty-two patients with mild, moderate, and severe SUI were treated once and followed for 3 and 6 months. Urodynamic studies, LUTS, and sexual function questionnaires (PBCC, USS, KHQ, and others) were assessed before and after the treatment.
3. OUTSTANDING RESULTS
Thirty-five women underwent the IncontiLase® procedure. Among the 28 women with baseline pad weights >1 g, 11 (39.3%) were objectively cured and 11 (39.3%) had improved. Among the 18 women with mild SUI, nine (50%) were cured and five (27.8%) had improved. Among the ten women with baseline pad weight >10 g, two (20%) were cured and six (60%) had improved. Data gained from different questionnaires also shows significant improvements. 40% of the partners of these patients reported improved sexual function.
4. CLINICALLY MEANINGFUL IMPROVEMENT IN SUI SYMPTOMS
Compared to surgical procedures, the IntimaLase® procedure seems to be very effective in the treatment of SUI and is not associated with any severe adverse effects. Further studies should be performed to assess the long-term sustained efficacy of this minimally invasive therapy.